AEterna Zentaris, Inc. (AEZS) - NASDAQ
  • Mon, May 9, 5:32 PM
    • AEterna Zentaris (NASDAQ:AEZS): Q1 EPS of -$0.37 beats by $0.37.
    • Revenue of $0.24M (+242.9% Y/Y) misses by $0.54M.
    • Shares +5.75% AH.
    • Press Release
    | Mon, May 9, 5:32 PM
  • Wed, Mar. 30, 6:51 AM
    • AEterna Zentaris (AEZS) Q4 results: Revenues: $0.1M (+900.0%); R&D Expense: $4.2M (-33.3%); SG&A: $5.7M (+21.3%); Operating Loss: ($9.9M) (+9.2%); Net Loss: ($10M) (-350.0%); Loss Per Share: ($1.46) (-123.9%).
    • FY2015 results: Revenues: $0.5M (+999%); R&D Expense: $17.2M (-27.4%); SG&A: $18.2M (+32.8%); Operating Loss: ($34.9M) (+6.7%); Net Loss: ($50.2M) (-191.9%); Loss Per Share: ($18.17) (+37.6%); Quick Assets: $41.5M (+18.9%).
    • No guidance given.
    | Wed, Mar. 30, 6:51 AM | 1 Comment
  • Tue, Mar. 29, 5:23 PM
    • AEterna Zentaris (NASDAQ:AEZS): Q4 EPS of -$1.46 misses by $0.16.
    • Revenue of $0.1M (+900.0% Y/Y) misses by $0.35M.
    • Press Release
    | Tue, Mar. 29, 5:23 PM | 3 Comments
  • Nov. 5, 2015, 5:21 PM
    • AEterna Zentaris (NASDAQ:AEZS): Q3 EPS of -$0.07 misses by $0.01.
    • Revenue of $0.2M misses by $0.25M.
    • Shares +12.5% AH.
    | Nov. 5, 2015, 5:21 PM
  • Aug. 14, 2015, 8:43 AM
    • Aeterna Zentaris (AEZS) Q2 results: Revenues: $0.2M; R&D Expense: $4.5M (-18.2%); SG&A: $3.7M (+27.6%); Operating Loss: ($8M) (+4.8%); Net Loss: ($15.1M) (-190.4%); Loss Per Share: ($0.14) (-55.6%); Quick Assets: $45.5M (+30.4%).
    • No guidance given.
    | Aug. 14, 2015, 8:43 AM
  • Aug. 13, 2015, 4:49 PM
    • AEterna Zentaris (NASDAQ:AEZS): Q2 EPS of -$0.14 misses by $0.06.
    • Revenue of $0.2M misses by $0.35M.
    • Shares -11.3%.
    | Aug. 13, 2015, 4:49 PM
  • May 7, 2015, 5:42 PM
    • AEterna Zentaris (NASDAQ:AEZS): Q1 EPS of -$0.13 misses by $0.03.
    • Revenue of $0.07M
    | May 7, 2015, 5:42 PM
  • Mar. 18, 2015, 6:56 AM
    • Aeterna Zentaris (AEZS -2.2%) Q4 results: License fees: $11K; R&D Expense: $6.3M (+18.9%); SG&A: $4.7M (+80.8%); Operating Loss: ($10.9M) (-36.3%); Net Income: $4.2M (+151.2%); EPS: $0.06 (+127.3%).
    • FY2014 results: License fees: $11K; R&D Expense: $23.7M (+11.3%); SG&A: $13.7M (+11.4%); Operating Loss: ($37.4M) (-36.0%); Net Loss: ($16.6M) (-344.1%); Loss Per Share: ($0.28) (-216.7%); Quick Assets: $34.9M (-19.2%).
    • No guidance given.
    | Mar. 18, 2015, 6:56 AM | 3 Comments
  • Mar. 17, 2015, 4:21 PM
    • AEterna Zentaris (NASDAQ:AEZS): Q4 EPS of $0.06 beats by $0.22.
    | Mar. 17, 2015, 4:21 PM | 2 Comments
  • Nov. 4, 2014, 5:16 PM
    • AEterna Zentaris (NASDAQ:AEZS): Q3 EPS of -$0.20 misses by $0.04.
    | Nov. 4, 2014, 5:16 PM
  • Oct. 28, 2014, 1:02 PM
    • Aeterna Zentaris (AEZS +0.8%) will report Q3 results on November 4 after the close. The conference call will begin the next day, November 5, at 8:30 am ET.
    • Consensus view is a loss of ($0.16) per share.
    | Oct. 28, 2014, 1:02 PM
  • Aug. 8, 2014, 11:30 AM
    • Aeterna Zentaris (AEZS) Q2 results: Revenues: $0; Operating Loss: ($8.4M) (+13.2%); Net Loss: ($5.0M) (-153.8%); Loss Per Share: ($0.09) (-125.0%); Quick Assets: $40.0M (-8.4%).
    • No financial guidance given.
    | Aug. 8, 2014, 11:30 AM | 1 Comment
  • Aug. 7, 2014, 6:38 PM
    • AEterna Zentaris (NASDAQ:AEZS): Q2 EPS of -$0.09 beats by $0.10.
    | Aug. 7, 2014, 6:38 PM
  • May 8, 2014, 6:17 PM
    • Aeterna Zentaris (AEZS): Q1 EPS of -$0.08 beats by $0.22.
    | May 8, 2014, 6:17 PM | 2 Comments
  • Mar. 20, 2014, 4:40 PM
    • AEterna Zentaris, Inc. (AEZS): Q4 EPS of -$0.22 misses by $0.18.
    | Mar. 20, 2014, 4:40 PM | 1 Comment
Company Description
AEterna Zentaris, Inc. engages in the development of novel treatments in oncology and endocrinology, which currently investigating treatments for various unmet medical needs. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed... More
Sector: Healthcare
Industry: Biotechnology
Country: Canada